| 1 |
Dose-finding Study for AdimrSC-2f Vaccine |
COVID-19 |
Biological: AdimrSC-2f |
Adimmune Corporation |
Phase 1|Phase 2 |
NCT05104489 |
2022-01-03 |
| 2 |
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine |
Covid19 |
Biological: SARS-CoV-2 Protein Subunit Recombinant Vaccine|Biological: SARS-CoV-2 Inactivated Vaccine |
PT Bio Farma|Fakultas Kedokteran Universitas Indonesia|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia |
Phase 1 |
NCT05067894 |
2021-12-10 |
| 3 |
Safety and Tuberculin Conversion Following BCG Vaccination |
BCG Vaccination Reaction |
Biological: BCG vial vaccine|Biological: BCG ampoule vaccine |
PT Bio Farma|Dr. Soetomo General Hospital |
Phase 2 |
NCT05124340 |
2021-12-01 |
| 4 |
Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Sub-Acute Stroke Infarct |
Ischemic Stroke |
Biological: Conditioned Medium|Biological: Umbilical Cord Mesenchymal Stem Cells|Procedure: Neurologic and Neutrophic Drugs |
PT. Prodia Stem Cell Indonesia |
Phase 1|Phase 2 |
NCT05008588 |
2021-09-01 |
| 5 |
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III |
COVID-19 Pandemic |
Biological: Recombinant SARS-CoV-2 fusion protein vaccine (V-01)|Other: Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) |
Livzon Pharmaceutical Group Inc. |
Phase 3 |
NCT05096845 |
2021-08-25 |
| 6 |
A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above |
COVID-19|SARS-CoV-2 |
Biological: SARS-CoV-2 mRNA Vaccine|Biological: Placebo |
Walvax Biotechnology Co., Ltd.|Abogen Biosciences Co. Ltd.|Yuxi Walvax Biotechnology Co., Ltd. |
Phase 3 |
NCT04847102 |
2021-07-22 |
| 7 |
A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells) |
COVID-19 |
Biological: Recombinant COVID-19 vaccine (Sf9 cells)|Other: Placebo control |
WestVac Biopharma Co., Ltd.|West China Hospital |
Phase 3 |
NCT04904471 |
2021-06-15 |
| 8 |
Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19 |
COVID-19 |
Biological: AV-COVID-19 |
Aivita Biomedical, Inc.|PT AIVITA Biomedika Indonesia|Kariadi Hospital|Central Army Hospital RSPAD Gatot Soebroto |
Phase 2 |
NCT05007496 |
2021-04-14 |
| 9 |
Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients |
Covid 19 |
Biological: Normoxic Allogenic UCMSC|Other: Normal saline solution |
Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia|Dr. Moewardi General Hospital, Surakarta, Indonesia|Dr. Sardjito General Hospital, Yogyakarta, Indonesia|Dr. Hasan Sadikin General Hospital, Bandung, Indonesia|PT Bifarma Adiluhung |
Phase 2|Phase 3 |
NCT05132972 |
2021-01-17 |
| 10 |
A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19 |
Prevention of COVID-19|Safety and Efficacy |
Biological: Recombinant new coronavirus vaccine (CHO cell) group|Biological: Recombinant new coronavirus vaccine (CHO cells) placebo group |
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
Phase 3 |
NCT04646590 |
2020-12-16 |
이 누리집은 대한민국 공식 전자정부 누리집입니다.